Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dalton Pharma Services and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.
Subscribe to our email newsletter
Utilizing enzyme-based technology developed at Thermo Fisher Scientific’s Milwaukee, Wisconsin, molecular bioreagents facility, Dalton will produce poly-inosine (Poly-I) and poly-cytosine (Poly-C) in accordance with cGMP regulations.
Poly-I and Poly-C are polynucleotides that are used as adjuvants, or catalysts, to stimulate an immune response when combined with other substances in a drug. Dalton will supply these polynucleotides to Oncovir, which will use Poly-I and Poly-C in vaccine development.
Peter Pekos, president and CEO of Dalton Pharma Services, said: “The agreement is timely due to an increased demand for commercial quantities of these molecules as adjuvants for new vaccines. And, this partnership recognizes Dalton’s expertise in cGMP manufacturing and analysis of complex molecules under cGMP conditions.”